OPTIMAL's health economics program is examining the costs and benefits of immunoglobulin therapy in blood cancers from both health-system and patient perspectives. Economic models bring together clinical outcomes, quality of life and health-service data to understand when Ig provides meaningful value and to inform evidence-based treatment decisions.

Our projects include:

• Discrete choice experiments: 

  • Clinicians: Examining how clinicians weigh infection risk, dosing, costs and clinical uncertainty when deciding whether to start or stop Ig.

  • Patients: Exploring how patients value infection prevention, treatment burden, route and setting of administration, adverse-event risks and quality-of-life impacts. 

• Modelling Ig demand in patients with blood cancers 

• TRUST-Ig: Identifying the true cost of immunoglobulin

• Initiation and discontinuation of IgRT in myeloma

• Cost-effectiveness of IgRT in Multiple Myeloma:

  • Recurrent infection risk prediction for infection prevention decision-making

  • Cost of treating serious infections and IgRT in MM

  • Infection seasonality to better optimise IgRT criteria